|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
36,570,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for its lead product candidate RenovoGem™. Co.'s therapy platform, RenovoRx Trans-Arterial Micro-Perfusion, or RenovoTAMP™ utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
32,000 |
42,000 |
206,145 |
378,273 |
| Total Buy Value |
$27,200 |
$36,497 |
$185,286 |
$185,286 |
| Total People Bought |
1 |
2 |
4 |
6 |
| Total Buy Transactions |
3 |
5 |
17 |
22 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-09-11 |
2025-06-10 |
2024-12-10 |
2023-12-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Agah Ramtin |
Chief Medical Officer |
• • – |
2025-12-05 |
4 |
B |
$0.96 |
$9,600 |
D/D |
10,000 |
766,460 |
2.81 |
- |
|
| Agah Ramtin |
Chief Medical Officer |
• • – |
2025-11-24 |
4 |
B |
$0.80 |
$9,600 |
D/D |
12,000 |
756,460 |
2.81 |
- |
|
| Agah Ramtin |
Chief Medical Officer |
• • – |
2025-11-21 |
4 |
B |
$0.80 |
$8,000 |
D/D |
10,000 |
744,460 |
2.81 |
- |
|
| Bagai Shaun |
Chief Executive Officer |
• • – |
2025-08-25 |
4 |
B |
$0.91 |
$4,549 |
D/D |
5,000 |
330,040 |
2.73 |
- |
|
| Bagai Shaun |
Chief Executive Officer |
• • – |
2025-08-22 |
4 |
B |
$0.95 |
$4,748 |
D/D |
5,000 |
325,040 |
2.73 |
- |
|
| Agah Ramtin |
Chief Medical Officer |
• • – |
2025-06-05 |
4 |
B |
$1.40 |
$29,400 |
D/D |
21,000 |
734,460 |
2.81 |
- |
|
| Marton Laurence |
Director |
– • – |
2025-05-02 |
4 |
OE |
$0.15 |
$3,072 |
D/D |
20,480 |
66,164 |
|
- |
|
| Agah Ramtin |
Chief Medical Officer |
• • – |
2025-04-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
400,000 |
713,460 |
|
- |
|
| Agah Ramtin |
Chief Medical Officer |
• • – |
2025-04-15 |
4 |
B |
$0.90 |
$13,500 |
D/D |
15,000 |
1,113,460 |
2.81 |
- |
|
| Bagai Shaun |
Chief Executive Officer |
• • – |
2025-04-15 |
4 |
B |
$0.91 |
$6,821 |
D/D |
7,500 |
320,040 |
2.81 |
- |
|
| Agah Ramtin |
Chief Medical Officer |
• • – |
2025-04-11 |
4 |
B |
$0.80 |
$16,000 |
D/D |
20,000 |
1,098,460 |
2.81 |
- |
|
| Kocak Ron |
VP Controller and PAO |
• – – |
2025-04-10 |
4 |
B |
$0.79 |
$5,135 |
D/D |
6,500 |
12,595 |
2.74 |
- |
|
| Kocak Ron |
VP Controller and PAO |
• – – |
2025-04-09 |
4 |
B |
$0.80 |
$4,800 |
D/D |
6,000 |
6,095 |
2.66 |
- |
|
| Agah Ramtin |
Chief Medical Officer |
• • – |
2025-04-09 |
4 |
B |
$0.81 |
$24,399 |
D/D |
30,000 |
1,078,460 |
2.81 |
- |
|
| Bagai Shaun |
Chief Executive Officer |
• • – |
2025-04-09 |
4 |
B |
$0.83 |
$8,300 |
D/D |
10,000 |
312,540 |
2.81 |
- |
|
| Kocak Ron |
VP Controller and PAO |
• – – |
2025-04-08 |
4 |
B |
$0.80 |
$76 |
D/D |
95 |
95 |
2.66 |
- |
|
| Agah Ramtin |
Chief Medical Officer |
• • – |
2025-04-08 |
4 |
B |
$0.84 |
$21,840 |
D/D |
26,000 |
1,048,460 |
2.81 |
- |
|
| Marton Laurence |
Director |
– • – |
2025-04-08 |
4 |
B |
$0.85 |
$10,218 |
D/D |
12,050 |
45,684 |
2.39 |
- |
|
| Bagai Shaun |
Chief Executive Officer |
• • – |
2025-04-07 |
4 |
B |
$0.83 |
$8,300 |
D/D |
10,000 |
302,540 |
2.81 |
- |
|
| Macfarlane Kirsten Angela |
Director |
– • – |
2024-01-26 |
4 |
B |
$0.00 |
$0 |
D/D |
40,983 |
40,983 |
2.31 |
- |
|
| Marton Laurence |
Director |
– • – |
2024-01-26 |
4 |
B |
$0.00 |
$0 |
D/D |
8,196 |
33,634 |
2.31 |
- |
|
| Agah Ramtin |
Chief Medical Officer |
• • – |
2024-01-26 |
4 |
B |
$0.00 |
$0 |
D/D |
40,983 |
47,460 |
2.73 |
- |
|
| Spiegel Robert J. |
Director |
– • – |
2024-01-26 |
4 |
B |
$0.00 |
$0 |
D/D |
40,983 |
40,983 |
2.31 |
- |
|
| Bagai Shaun |
Chief Executive Officer |
• • – |
2024-01-26 |
4 |
B |
$0.00 |
$0 |
D/D |
40,983 |
292,540 |
2.73 |
- |
|
| Nelms Angela |
Chief Operating Officer |
• – – |
2023-10-03 |
4 |
B |
$1.05 |
$1,151 |
D/D |
1,100 |
1,100 |
2.66 |
- |
|
33 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
